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Abstract: Alginates are widely used in tissue engineering technologies, e.g., in cell 
encapsulation, in drug delivery and various immobilization procedures. The success rates 
of these studies are highly variable due to different degrees of tissue response. A cause for 
this variation in success is, among other factors, its content of inflammatory components. 
There is an urgent need for a technology to test the inflammatory capacity of alginates. 
Recently, it has been shown that pathogen-associated molecular patterns (PAMPs) in 
alginate are potent immunostimulatories. In this article, we present the design and 
evaluation of a technology platform to assess (i) the immunostimulatory capacity of alginate 
or its contaminants, (ii) where in the purification process PAMPs are removed, and (iii) 
which Toll-like receptors (TLRs) and ligands are involved. A THP1 cell-line expressing 
pattern recognition receptors (PRRs) and the co-signaling molecules CD14 and MD2 was 
used to assess immune activation of alginates during the different steps of purification of 
alginate. To determine if this activation was mediated by TLRs, a THP1-defMyD88  
cell-line was applied. This cell-line possesses a non-functional MyD88 coupling protein, 
necessary for activating NF-κB via TLRs. To identify the specific TLRs being activated by 
the PAMPs, we use different human embryonic kidney (HEK) cell-line that expresses only 
one specific TLR. Finally, specific enzyme-linked immunosorbent assays (ELISAs) were 
applied to identify the specific PAMP. By applying this three-step procedure, we can 
screen alginate in a manner, which is both labor and cost efficient. The efficacy of the 
platform was evaluated with an alginate that did not pass our quality control. We 
demonstrate that this alginate was immunostimulatory, even after purification due to 
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reintroduction of the TLR5 activating flagellin. In addition, we tested two commercially 
available purified alginates. Our experiments show that these commercial alginates 
contained peptidoglycan, lipoteichoic acid, flagellin, and even lipopolysaccharides (LPS). 
The platform presented here can be used to evaluate the efficacy of purification procedures 
in removing PAMPs from alginates in a cost-efficient manner. 




Alginate is a commonly applied polymer in encapsulation research. Alginate was originally 
introduced for microencapsulation of pancreatic islets [1] but is now applied for immunoprotection of 
many other endocrine and recombinant cells. Currently it is applied for the delivery of therapeutic 
products [2,3], such as growth hormone and human clotting factor IX.9 production [4–7]. Also, it is used 
in bioartificial kidneys [8], for protection of hepatocytes [9], and for bioartificial parathyroids [10]. 
Alginate is being applied for both macro- and microencapsulation [11] as well as for enveloping cells 
in other fields of tissue engineering [12]. 
Alginate is a linear polysaccharide composed of 1,4′-linked β-D-mannuronic acid (M) and  
α-L-guluronic acid (G) residues in different sequences [13]. The ratio of G and M blocks is dependent 
on the source of algae used for alginate extraction [14]. Alginates with a high-G content are preferred 
for applications where a more rigid structure is required [15]. Alginates with a higher M content are 
preferred for applications where pliable structures are prioritized. This versatile property of alginate is 
caused by the higher affinity of the G residues for divalent ions [16]. The alginate that is most 
commonly applied for cell encapsulation is harvested from brown algae such as Laminaria 
hyperborea, Macrocystis pyrifera, Laminaria digitata, Ascophyllum nodosum, Laminaria japonica, 
Eclonia maxima, Lessonia nigrescens, Durvillea antarctica and Sargassum spp. [17]. 
A persistent issue in application of alginate is the different degree of biocompatibility, which seems to 
be laboratory dependent [18,19]. Different factors such as the use of different types of alginates [20], the 
type of coating [13] and variations in purity of alginate have been shown to be a major cause of the 
variations in success of the capsules in terms of biocompatibility and acceptance by the host [21–23]. 
Also, items such as capsule porosity is a criteria for cell survival [16,24] as well as stiffness that might 
influence cell differentiation [2]. Purification of alginate is reported to reduce inflammatory responses 
against alginate based capsules but many groups have difficulties in reliably producing ultrapure 
alginates [20,25,26]. Another issue is that many used procedures to purify alginate have been 
published [22,27] but techniques to predict whether the purification is efficacious are lacking. 
Recently, we demonstrate that pathogen-associated molecular patterns (PAMPs) in alginates are 
one of the dominant molecules responsible for tissue responses after implantation of encapsulated 
tissues or cells [28]. PAMPs are small molecular motifs found on groups of microorganisms and can 
be recognized by Toll-like receptors (TLRs) and other pattern recognition receptors (PRRs) on cells of 
the innate immune system [29]. In the present study, we applied this knowledge to design a technology 
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platform that can be used to evaluate the efficacy of purification procedures for alginate. The platform 
is composed of several fast and cost-effective procedures designed to (i) stepwise assessment of the 
immunostimulatory capacity of alginate, (ii) wherein the purification process the PAMPs are removed, 
and (iii) which TLRs and their ligands are being involved and might result in a smaller sample size 
required for biocompatibility and animal testing. 
2. Results 
2.1. Design of a Technology to Identify PAMPs in Alginate 
The very first step in the platform was a fast screening for NF-κB based immunostimulation of 
THP1-XBlue™-MD2-CD14 monocytes by the alginate samples. If pathogen-associated molecular 
patterns (PAMPs) are absent in the alginate, the cells will not be activated, but when PAMPs in the 
range of picograms are present the cells will react [28,30]. 
The next step was to determine whether the PAMPs are ligands for Toll-like receptors (TLRs) NOD 
receptors or other pattern recognition receptors (PRRs). To this end, we tested the alginate on  
THP1-XBlue™-MD2-CD14–defMyD88 cells. These cells have a nonfunctional MyD88 signaling. All 
TLRs with the exception of TLR3 require MyD88 for NF-κB activation. If the cells give no  
signal—which up to now happened with all alginates tested—we continued to the next step. 
In order to identify the exact type and amount of PAMP in a stepwise fashion in the alginate, we 
employed a relatively inexpensive test involving transgenic human embryonic kidney (HEK) cells 
with one specific TLR. Also, these cells carry a NF-κB reporter allowing fast identification of the TLR 
involved. The last step in the platform was application of ELISAs to identify the specific PAMP in the 
alginate (Figure 1). 
The advantage of the above described work flow is that it avoids a time consuming and expensive 
screening for non-specific PAMPs by ELISAs only. Another advantage is that it provides data on 
immunostimulatory capacity of the alginate preparations. 
2.2. Application of the Technology to Test the Efficacy of Alginate Purification Procedures 
The most commonly applied procedure to purify alginate is chemical extraction of contaminant [25,31]. 
As outlined in the materials and methods, our published procedure was composed of six distinct  
steps that were originally introduced as extraction steps for differentially charged proteins [21]. The 
above-presented technology was applied to demonstrate the efficacy of the purification procedure in 
removing PAMPs. In order to demonstrate the efficacy of the technology for screening the adequacy 
of the purification procedure, we showed here an example of a purification-run in which the end 
product contained a novel introduced contamination that was not present in the crude alginate. This 
alginate had not passed the screening as a result of the screening and had not been applied for 
encapsulation research in vivo. 
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Figure 1. Technology to assess the immunostimulatory capacity of alginate, to determine 
where in the purification process the pathogen associated molecular patterns (PAMPs) are 
removed, and which Toll-like receptors (TLRs) and ligands are being involved. We applied 
a THP1 monocytic cell-line in the first step to determine the immunostimulatory capacity 
of the alginate. Next, we applied a THP1 with a non-functional MyD88 coupling protein. 
This allowed us to confirm that the immune stimulation is PRR dependent. In the next step, 
HEK cell-lines that possess the specific receptors were applied. This approach allows for 
scaling down the number of candidate PAMPs that might be responsible for the response. 
The last step was application of an enzyme-linked immunosorbent assays to identify the 
specific PAMPs. 
 
Alginates from all six steps were applied for testing on THP1-XBlue™-MD2-CD14 monocytes. As 
shown in Figure 2a, the first step, i.e., filtration was the most efficacious step in removing THP1 
immunostimulating contaminations. The immunostimulatory capacity remained low after the next 
steps but gradually increased toward step 6. 
Next, the samples were cultured with THP1-XBlue™-MD2-CD14–defMyD88 cells that lack a 
functional TLR signaling. As shown in Figure 2b, there was no activation of NF-κB in the absence of 
MyD88 illustrating that the activation is TLR dependent. 
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Figure 2. (a) Activation of NF-κB in THP1 reporter cell line to determine the 
immunostimulatory capacity of alginate in the six different steps of purification. (b) This 
activation was completely MyD88 dependent as it was not present in THP1 cell-line that 
has a non-functional MyD88. Activation of NF-κB was almost completely gone after the 
first steps of purification. Values are presented as mean ± SD (n = 5). All the purification 
steps presented a statistically significant response (p < 0.001) when compared with crude 
alginate (step 0) or with purified alginate (step 6). LPS (1 µg/mL) was used as positive 
control for the THP1-cell line, and induced an activation of NF-κB of 1.039 ± 0.081. For the 
THP1 cell line presenting a MyD88 non-functional protein, Tri-DAP (10 µg/mL) was used 
as a positive control, with a NF-κB activation of 0.053 ± 0.006. 
 
2.3. Stimulation of TLR2, 4, 5, and 9 by Impurities in Alginates during Purification Steps 
To identify the specific TLRs involved, we used human embryonic kidney (HEK) cells expressing 
the specific MyD88 dependent Toll-like or Nod-like receptors. Table 1 shows the percentage change 
when HEK cell-lines with TLR2, 3, 4, 5, 7, 8, and 9, and NOD1 and 2 were stimulated with the 
(partly) purified alginates. Specific activation was found for TLR2, 4, 5 and 9 but not for TLR3, 7 and 
8 and neither for NOD1 and 2. Activation was reduced to that of the negative controls after the 
filtration steps for TLR9, but not for TLR2, TLR4 and TLR5. TLR2 was activated from steps 1–5  
(p < 0.05). It was deleted in the final purification step, i.e., step 6. TLR4 was activated from step 0–6 
(p < 0.01). TLR5 was activated by alginate obtained from step 0 and 2 (p < 0.01), but was no longer 
activated by alginate obtained as of step 3. A statistical significant activation of TLR9 was found 
during the last step of purification, illustrating that novel PAMP contaminations can be introduced 
during the purification procedures (p < 0.01). 
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Table 1. Percent change of NF-κB in HEK cell-lines with specific Toll-like receptors 
(TLRs) when stimulated with alginate in the different steps of purification. Contaminations 
can activate hTLR2, 4, 5 and 9. Values are presented as percentages. Each cell-line was 
stimulated with an appropriate positive control with different values of NF-κB activation:  
(a) TLR2 (FSL-1, 1 µg/mL, 1.272 ± 0.057); (b) TLR3 (Poly(I:C) HMW, 5 µg/mL,  
0.217 ± 0.015); (c) TLR4 (LPS-EK Ultrapure, 100 ng/mL, 0.270 ± 0.009); (d) TLR5 
(RecFLA-ST, 100 ng/mL, 2.626 ± 0.023); (e) TLR7 (Imiquimod (R837), 50 µg/mL,  
0.154 ± 0.056); (f) TLR8 (ssRNA 40, 50 µg/mL, 0.065 ± 0.009); (g) TLR9 (ODN 2006, 
100 µg/mL, 1.088 ± 0.051); (h) NOD1 (Tri-DAP, 10 µg/mL, 0.458 ± 0.068); (i) NOD2 
(L18-MDP, 100 ng/mL, 0.504 ± 0.069). DMEM 1640 growth media was used in all the 
cell lines as a negative control. The threshold for biologically relevant was higher than 0.01 
(arbitrary units). This level is the minimum value that purified alginate in solution can reach. 
Values are presented as percent change; p < 0.05 (*) and p < 0.01 (**). 
HEK 
cell-line 
Purification steps Positive 
control 0 1 2 3 4 5 6 
TLR2 −20.2 143.7 * 149.6 * 108.4 * 115.1 * 155.1 * −30.8 1461.7 
TLR3 0.5 −12.2 2.9 2.6 4.4 6.2 4.9 418.8 
TLR4 108.1 ** 70.5 ** 43.4 ** 38.0 ** 43.0 ** 65.2 ** 67.7 ** 324.1 
TLR5 20.1 ** −3.8 28.7 ** 1.8 −8.3 12.0 −4.5 1878.9 
TLR7 4.86 11.15 −5.42 −4.83 0.58 1.90 −0.85 104.10 
TLR8 −31.64 −1.83 6.00 −6.74 −1.22 4.74 −28.35 11.11 
TLR9 6.35 2.40 −1.52 −2.46 −2.13 5.83 103.5 ** 1033.33 
NOD1 7.18 −5.42 −1.00 −0.72 1.28 2.53 4.13 818.94 
NOD2 −4.44 −12.00 −13.47 −11.28 −14.45 −10.87 −7.46 451.05 
2.4. PAMPs Flagellin and Peptidoglycan are Present during the Purification Steps 
As a last step, we applied ELISAs directed against the ligands of the TLRs found in the HEK  
cell-lines based assays. To this end, we screened for common and specific molecules known for 
triggering an immune response in the stimulated TLR2 (lipoteichoic acid, LTA; peptidoglycan, PG), 
TLR4 (lipopolysaccharides, LPS), TLR5 (Flagellin) and TLR9 (unmethylated CpG, CpG-ODN). In 
crude alginate and in all the steps of purification, we found PG and Flagellin, which were responsible 
for activation of HEK cell-lines carrying hTLR2 and 5. Figure 3 shows both PG and Flagellin were 
found as of the beginning and could not be totally removed by the purification steps. We could not find 
LTA, CpG-ODN or LPS (Figure 3). 
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Figure 3. (a) Peptidoglycan and (b) flagellin concentration in the different purification 
steps of intermediate-G alginate. Lipoteicoic acid (LTA; TLR2 ligand), 
lipopolysaccharides (LPS; TLR4 ligand) and unmethylated CpG (CpG-ODN; TLR9 
ligand) were not detected. Experiments were performed in triplicates. 
 
2.5. Immunostimulatory Capacity of Commercially Available Purified Alginates 
Next, we applied our toolbox to test the adequacy of two commercially available alginates that are 
marketed as purified alginate. These were alginates purchased from Pronova (Pronova UltraPure medium 
viscosity (MVG), G/M ratio ≥ 1.5, G content ≥ 60%, approximate Mw > 200 kDa, endotoxins ≤ 100 EU/g, 
viscosity > 200 mPa·s) and Les Laboratoires Brothier (now Kimica Algin High G I-3G, viscosity  
300–400 mPa·s). As shown in Figure 4, both alginates still had immunostimulatory capacity. When 
compared to the alginate mentioned in Figure 2a, the commercial alginates were equally or even more 
immunostimulatory (Figure 4). 
Figure 4. Immune activation by commercially available ultrapure alginate and alginate as 
shown in the previous graphs. The right bar indicated our own procedure of purification, 
i.e., how it is performed at the University Medical Center Groningen (UMCG).Values are 
presented as mean ± SD. LPS was used as a positive control, which induced a NF-κB 
activation of 2.070 ± 0.135. The difference between our purification proceeding and the 
one from Laboratoires Brothier was statistically significant (p < 0.01, **). 
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Due to immune activation found in commercially available alginate, we applied ELISAs to identify 
the type of contamination responsible for immunostimulation. Alginate from Pronova contained 
peptidoglycan and lipoteichoic acid (TLR2 ligands), while the alginate from Les Laboratoires Brothier 
contained peptidoglycan (TLR2 ligand) and lipopolysaccharides (TLR4 ligand) (Figure 5). This 
demonstrated the need of a platform as presented here to test also commercially obtained alginates. 
Figure 5. Presence of (a) peptidoglycan (PG; TLR2 ligand); (b) lipoteichoic acid (LTA; 
TLR2 ligand); (c) lipopolysaccharides (LPS, TLR4 ligand) in commercially available 
ultrapure alginate of Pronova and Laboratoires Brothier. 
 
3. Discussion 
In this study, we present a novel technology platform to test for the presence of (i) 
immunostimulatory capacity of alginate, (ii) where in the purification process PAMPs are removed, 
and (iii) which TLR and ligands are involved. The principal applicability of the platform was 
evaluated with an alginate that normally would not pass our criteria for application in in vivo studies to 
demonstrate its potential and usefulness in testing efficacy of our procedure. Prior to this research, 
only implantation studies involving rats and mice have been used. This is time-consuming, presents 
ethical issues, and is costly. Our approach is less labor intensive, relatively fast, and affordable. 
Also, our platform allows for fast screening of commercially available alginates which are presently 
being applied and are considered to be ultrapure. The samples that we bought were actually not 
ultrapure and already gave immunostimulatory signals as of the first step. The Pronova alginate is the 
most commonly applied alginate [14,24,27,32–34]. In our test sample, it was found to contain 
peptidoglycan (PG) and lipoteichoic acid (LTA). According to the manufacturer, it is ultrapure and 
below reliable quantification of endotoxin levels by the Limulus amebocyte lysate (LAL) assay. Here, 
it is shown that the level of contaminant is enough to induce an immune reaction and detectable with 
our platform. The other alginate from Les Laboratoires Brothier contains PG and lipopolysaccharides 
(LPS). With our standards, it would not pass the criteria for in vivo application. Alginates should be 
free of these contaminants when applied in vivo [20,22,27]. 
Prior to our research, the LAL assay was applied to test for presence of endotoxins [35]. LAL is an 
extract of blood cells from the horseshoe crab, Limulus polyphemus. We recommend use of more 
specific measures such as the ELISA approach instead of LAL for the following reason: LAL has been 
considered to react mainly with bacterial lipopolysaccharide (LPS). Although it has recently been 
shown that also the presence of lipoteichoic acid (LTA) and peptidoglycan (PG) [35] may result in 
positive LAL assays, it is unknown how sensitive the assay for other endotoxins or PAMPs is. In 
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addition, our platform provides insight concerning which PAMPs are still present in alginate, which 
gives researchers the opportunity to design specific means to remove the molecules. 
As shown in the present study, stepwise filtration towards 0.45 µm filters is an effective method to 
remove most of the PAMPs present in crude alginate. At the same time, we demonstrate with the 
example that new contaminations with PAMPs can be introduced during the purification course. The 
causes of these new contaminations with PAMPs may be multifactorial. The applications of forceps 
that might contain bacteria, funnels that have been previously flushed with demi-water or exposure to 
non-sterile atmospheric air are sources for bacterial contaminations and thus PAMPs. It is crucial to 
use endotoxin free water for all solutions and when washing all equipment in order to avoid 
introduction of contaminants to reproduce a high purity alginate. 
A common issue in the application of our platform is that specific TLRs are being activated while the 
ligand cannot be detected with ELISA. This should be explained as follows: Many TLRs have more 
ligands [30] than the classically described such as LTA for TLR2, CpG-ODN for TLR9 or LPS for 
TLR4. We have to be aware that activation can occur via other molecules not described yet [36–38]. It 
might even be specific alginate molecules such as small molecular poly-MM that can bind to TLR4 
and CD14 [39]. We believe, however, that these molecules should be removed in order to facilitate 
biocompatibility. Therefore, it is important to not only apply ELISAs for screening purity, but also test 
whether TLRs are activated by the purified alginate. 
Most purification procedures for alginate were originally designed to remove proteins [22]. Our data 
indicates that proteins are not very immunostimulatory as evidenced by the samples from step one where 
no protein extraction was performed and there was barely an immunostimulatory on THP1 cells. This 
supports our previous findings [28] but it does not seem to corroborate the findings of Ménard et al. [27] 
who study the protein content of both commercial and own purified alginates and found a correlation 
with immunostimulatory capacity of the studied alginates. It is, however, difficult if not impossible to 
compare our results with Ménard et al. [27] since knowledge concerning the role of PAMPs was not 
available at the time their research was conducted. In our research, when PAMPs were absent, the 
proteins in the alginate are not immunostimulatory. 
The lack of immunostimulatory effects of alginates still containing proteins does not suggest that 
there is no need to remove proteins. As shown in previous studies [40], the formation of an adequate, 
persisting membrane of poly-l-lysine (PLL) is a delicate matter. Proteins present in crude alginate 
make the process of binding of PLL more complex and less predictable and should therefore be avoided. 
In recent reviews [41,42], it has been emphasized that the area of tissue engineering in which 
alginate is commonly applied is characterized by a low degree of reproducibility and lack of assays to 
compare materials between laboratories. This has been one of the principle reasons for designing and 
publishing this research. It is our hope that the current research will contribute to a better 
understanding of the composition and immunostimulatory capacity of the alginates applied in the 
different studies that will make interpretation and comparison more adequate. 
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4. Materials and Methods 
4.1. Chemicals 
Intermediate-G alginate (ISP Alginates Ltd., Ayrshire, UK) has been used (42% G-chains,  
58% M-chains, 23% GG-chains, 19% GM-chains, 38% MM-chains, Mn = 428 kDa) for studies on 
efficacy of purification. The composition of these alginate samples was studied by proton nuclear 
magnetic resonance (
1
H-NMR). Commercially available purified alginates from Les Laboratoires 
Brothier (Paris, France) and Pronova™ (FMC BioPolymer, Sandvika, Norway) were applied to 
compare the degree of purity and content of pathogen-associated molecular patterns. 
QUANTI-Blue™ (InvivoGen, Toulouse, France) is a medium with a colorimetric enzyme used to 
detect activity of any alkaline phosphatase. QUANTI-Blue
™
 medium turns purple-blue in the presence of 
alkaline phosphatase (SEAP) and can be quantified using a spectrophotometer at 620–655 nm. 
4.2. Purification 
A commonly applied chemical-purification method is applied [21]. This chemical extraction method 
does not influence the alginate gelling condition [22]. The purification procedure was categorized into 
six distinct steps. After each step a sample was taken to assess the immunostimulatory capacity in order 
to gain insight in the efficacy of removing immunostimulatory contaminants in the alginate. 
Step 0: a sample from crude non-purified alginate was taken. 
Step 1: crude sodium alginate was dissolved at 4 °C in a 1 mM sodium ethylene glycol tetraacetic 
acid (EGTA) solution to a 1% solution under constant stirring. Subsequently, the solutions were 
filtered over successively 5.0, 1.2, 0.8, and 0.45 μm filters (Whatman®, Dassel, Germany). During this 
filtration step, all visible aggregates were removed. 
Step 2: the pH of the solution was lowered to 3.5 by addition of 2 N HCl + 20 mM NaCl. The 
solution was kept on ice to prevent hydrolysis of alginate. The next step was to slowly lower the pH 
from 3.5 to 2.0. This is associated with gradual precipitation of alginate as alginic acid [43]. Routinely, 
the solutions were brought at a pH of 2.0 and subsequently filtered over a Buchner funnel (pore size 
1.5 mm) to wash out non-precipitated contaminants. To extend the washout of non-precipitated 
contaminants, the precipitate was brought in 0.01 N HCl + 20 mM NaCl, vigorously shaken, and 
filtered again over the Buchner funnel. This washing procedure was performed three times and another 
sample was taken. 
Step 3: proteins were removed by extraction with chloroform/butanol [44]. The alginic acid was 
suspended in 100 mL of 0.01 N HCl + 20 mM NaCl and supplemented with chloroform (20 mL at 
each 100 mL alginate solution) and 1-butanol (5 mL at each 100 mL alginate solution). The mixture 
was vigorously shaken for 30 min and filtered over the Buchner funnel. This chloroform/butanol 
extraction was performed three times and a third sample was obtained after the last extraction. 
Step 4: the alginic acid was brought in water and slowly dissolved by gradually raising the pH to 
7.0 by slow addition of 0.5 N NaOH + 20 mM NaCl over a period of at least one hour. The alginate 
solution obtained was subjected to a chloroform/butanol extraction to remove those proteins which can 
only be dissolved in chloroform/butanol at neutral pH [44]. The solution was vigorously shaken in a 
mixture of chloroform (20 mL at each 100 mL alginate solution) and 1-butanol (5 mL at each 100 mL 
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alginate solution) for 30 min. The mixture was centrifuged for 5 min at 1800 rpm, which induced the 
formation of a separate chloroform/butanol phase, which was removed by aspiration. The extraction 
was repeated once and then a sample was taken. 
Step 5: the last step is precipitation of the alginate with ethanol [43]. To each 100 mL of alginate 
solution we added 200 mL of absolute ethanol. After an incubation period of 10 min, all alginate had 
precipitated. The alginate was filtered over the Buchner funnel and washed two times with absolute 
ethanol and a sample was obtained. 
Step 6: subsequently, the alginate was washed three times with ethylether and the last sample of 
purified alginate was taken (Figure 6). 
Figure 6. The applied chemical extraction of contaminants of alginate and the six distinct 
steps in the purification procedure. 
 
All the samples of alginate were freeze-dried (Freezone 2.5 Plus, Labconco, Kansas, MO, USA) 
overnight for immunostimulation and enzyme-linked immunosorbent assays (ELISAs). 
4.3. Immunostimulation by Alginates and Identification of Pattern Recognition Receptors Involved 
To determine the immunostimulatory capacity of samples of alginates obtained from the different 
steps of purification, we dissolved the alginate at a concentration of 0.3% (w/v) in a solution of  
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Krebs-Ringer-Hepes (KRH) with an appropriate osmolarity. Subsequently, alginate solutions were  
co-incubated with different cell lines (InvivoGen) expressing pattern recognition receptors (PRRs) under 
the control of a reporter gene. First, the sample was co incubated with THP1-XBlue™-MD2-CD14. 
THP1-XBlue™-MD2-CD14 expresses all Toll-like receptors (TLRs) [13,28,30]. We applied a  
NF-κB/AP-1 transcription that endogenously expresses all TLRs and additional inserts for the  
co-signaling molecules CD14 and MD2. This facilitates TLR-mediated responses [45]. In addition, we 
applied a THP1 cell expressing only a truncated, non-functional form of the TLR adapter MyD88  
(THP1-XBlue™-defMyD). MyD88 is an essential coupling messenger in the cascade from TLR and 
nucleotide-binding oligomerization domain receptors (NODs) activation towards NF-κB activation. 
Also, we applied human embryonic kidney (HEK)-cells overexpressing a specific TLR or NOD. The 
HEK-Blue™ cell-lines are produced by co-transfection of human TLR (2, 3, 4, 5, 7, 8 or 9), MD-2 and 
CD14 co-receptor genes into the HEK 293 cells. These are designed to identify the activation of specific 
human TLR2, 3, 4, 5, 7, 8 or 9 and NOD1 or 2 combined with AP-1 and a NF-κB reporter construct. 
The cell-lines THP1-XBlue™-MD2-CD14 and THP1-XBlue™-defMyD88 cells were cultured in 
Roswell Park Memorial Institute (RPMI) 1640 culture medium (supplemented with 2 mM·L-glutamine, 
1.5 g/L sodium bicarbonate, 4.5 g/L, 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) and 1.0 mM sodium pyruvate, with 10% fetal bovine serum (deactivated phosphatases)). The 
medium also contains 100 µg/mL Normocin™ and Pen-Strep (50 U/mL–50 µg/mL). The cells were 
plated at a concentration of 1 × 10
6
 cells/mL in 96-wells plates. Cells were stimulated with samples of 
alginates obtained from the different steps of purification (n = 5) and cultured overnight at 37 °C and 5% 
CO2. As positive controls, lipopolysaccharide from Escherichia coli K12 strain (LPS-EK Ultrapure  
10 µg/mL, InvivoGen) was used for the THP1-XBlue™-MD2-CD14 cell line and L-Ala-γ-D-Glu-mDAP 
(Tri-DAP 10 µg/mL, InvivoGen) for the THP1-XBlue™–defMyD88 cell line. RPMI 1640  
culture medium served as was used as a negative control. SEAP was quantified by using  
QUANTI-Blue™ (InvivoGen). 
HEK-Blue™ cells were suspended in Dulbecco’s Modified Eagle’s culture medium (DMEM) 
supplemented with 4.5 g/L glucose, 10% (v/v) fetal bovine serum (deactivated phosphatases),  
Pen-Strep (50 U/mL–50 µg/mL), 100 µg/mL Normocin™ and 2 mM L-glutamine). Cells were seeded 
at the following concentrations; at 280.000 cells/mL (hTLRs 2 and NOD 1), 140.000 cells/mL (hTLRs 
4, 5 and NOD 2), 220.000 cells/mL (hTLRs 7 and 8), and 450.000 cells/mL (hTLR 9), in 96-wells 
plates according to standard protocols [28,32]. Each well was stimulated with samples of alginates in 
different steps of purification (n = 5) and cultured overnight at 37 °C and 5% CO2. DMEM culture medium 
served as negative control. TLRs’ signaling was always confirmed using the appropriate TLR or NOD 
ligand. These were TLR2, synthetic diacylated lipoprotein (FSL-1); TLR3, polyinosine-polycytidylic acid 
(poly(I:C) high molecular weight (HMW)); TLR4, ultrapure lipopolysaccharide from E. coli K12 strain 
(LPS-EK Ultrapure); TLR5, recombinant flagellin from Salmonella typhimurium (RecFLA-ST); TLR7, 
9-benzyl-8 hydroxyadenine (CL264); TLR8, 20-mer phosphorothioate protected single-stranded RNA 
oligonucleotide (ssRNA 40); TLR9, unmethylated CpG dinucleotides (Class B CpG 
oligodeoxynucleotide (ODN 2006); NOD1, L-Ala-γ-D-Glu-mDAP (Tri-DAP); and NOD2, synthetic 
derivative of muramyl dipeptide (L18-MDP). NF-κB activation was quantified by the SEAP activity 
using QUANTI-Blue™ (Invivogen). Experiments were repeated at least five times. 
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4.4. Measurement of Specific Pathogen-Associated Molecular Patterns (PAMPs) 
The presence of lipoteichoic acid (LTA; TLR2 ligand) was measured using a Human Lipoteichoic 
Acid ELISA Kit (Wuxi Donglin Sci&Tech Development Co. Ltd., Wuxi, Jiangsu, China). This ELISA 
is based on the competitive binding enzyme immunoassay technique. The samples were analyzed in 
triplicate, according to assay protocol. The enzyme-substrate reaction is terminated by the addition of 
0.05 mL of sulfuric acid solution and measured spectrophotometrically at a wavelength of 450 nm. All 
the incubations were performed at 37 °C and 5% CO2. 
The content of lipopolysaccharides (LPS; TLR 4 ligand) was measured using a Human 
Lipopolysaccharides ELISA Kit (Cusabio, Wuhan, China). For this assay, the quantitative sandwich 
enzyme immunoassay technique was employed, according to assay protocol. The optical density was 
measured at 450 nm within 5 min after the reaction was stopped. All the incubations were performed 
at 37 °C and 5% CO2. 
Quantification of flagellin (TLR5 ligand), human peptidoglycan (PG, TLR2 ligand), and 
unmethylated dsDNA (CpG-ODN, TLR9 ligand) was done with a Human Flagellin ELISA Kit, a 
Human Peptidoglycan (PG) ELISA kit, and a Human CpG oligodeoxynucleotide (CpG-ODN) ELISA 
kit (Qayee-Bio, Shanghai, China) according to assay protocols. The plates were read in a 
spectrophotometer at a relative optical density of 450 nm within 15 min after adding the stop solution. 
All the incubations were performed at 37 °C and 5% CO2. 
4.5. Statistical Analysis 
Results are expressed as mean ±SD. Statistical comparisons were made with the Mann Whitney U 
test using the GraphPad Prism 5.00 software (GraphPad Software, Inc., La Jolla, CA, USA).  
A p value<0.05 was considered statistically significant. 
5. Conclusions 
In the present study, we evaluated a technology platform designed for alginate to assess (i) the 
immunostimulatory capacity of alginate or its contaminants, (ii) wherein the purification process the 
PAMPS are removed or reintroduced, and (iii) which TLR and ligands are involved. We demonstrate 
the applicability by applying a purification run designed by our group and by testing two commercially 
available alginates which were marketed as ultrapure. These commercial ultrapure alginates contained 
ligands like peptidoglycan, lipoteichoic acid, flagellin, and even LPS. The activation of the immune 
system via TLRs and release of NF-κB was demonstrated in our platform. 
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